Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,958.40
(
0.72%
)
Dow Jones
49,447.43
(
0.00%
)
Brent Oil
95.16
(
0.15%
)
Bitcoin
78,370.38
(
2.67%
)
News Focus
News Focus
Post# of 257435
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 247704

Thursday, 07/20/2023 2:29:24 PM

Thursday, July 20, 2023 2:29:24 PM

Post# of 257435
VIR -45% on phase-2 failure in influenza:

https://finance.yahoo.com/news/vir-biotechnology-announces-topline-data-120000102.html

Vir Biotechnology…today announced that the Phase 2 PENINSULA trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints.

Why such a steep selloff? One reason is that VIR has tended to present itself to investors as all-powerful and all-knowing, which is perhaps a consequence of having George Scangos as (ex)CEO and having raised a huge amount of capital based on management’s reputation.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today